4-Aminophenylacetic acid (CAS: 1197-55-3) is an aromatic amino acid derivative with the molecular formula C8H9NO2. Its structure consists of a benzene ring bearing an amino group (-NH2) at the para position relative to a carboxymethyl group (-CH2COOH). As a versatile organic building block, 4-aminophenylacetic acid exhibits unique bifunctional reactivity: the aromatic amine enables diazotization, acylation, and Schiff base formation, while the carboxylic acid allows esterification, amidation, and salt formation. This dual functionality makes it an indispensable intermediate in the synthesis of beta-lactam antibiotics (especially cephalosporins), peptide coupling reagents, pharmaceutical impurities, and specialty fine chemicals. Its production typically involves reduction of 4-nitrophenylacetic acid or catalytic hydrogenation, and market demand is closely tied to the global pharmaceutical industry’s need for high-purity intermediates. Based on its chemical characteristics and industrial chain position, this article systematically analyzes international market dynamics of 4-aminophenylacetic acid, focusing on core application scenarios, competitive landscape, regional differences, regulatory trends, and future outlook, providing strategic references for industry participants.
Core Application Fields and Demand
Market demand for 4-aminophenylacetic acid is highly concentrated in three major areas: pharmaceutical intermediates (≈70% of global consumption), peptide synthesis and bioconjugation reagents (≈20%), and specialty fine chemicals including dyes, pigments, and polymer additives (≈10%). Its ability to participate in both electrophilic and nucleophilic reactions drives its widespread use.
In the pharmaceutical intermediate sector, 4-aminophenylacetic acid is a key precursor for the synthesis of cephalosporin antibiotics, particularly cefaclor, cefprozil, and other second- and third-generation cephalosporins. The compound’s amino group couples with activated side chain acids, while its carboxylic acid forms amide bonds with the cephalosporin core. With the global antibiotic market exceeding $40 billion annually and the rise of multi-drug-resistant infections driving demand for newer cephalosporins, consumption of high-purity 4-aminophenylacetic acid remains robust. Additionally, it is used in the synthesis of active pharmaceutical ingredients (APIs) for anti-inflammatory drugs, such as fenamic acid derivatives.
In peptide synthesis and bioconjugation, 4-aminophenylacetic acid serves as a linker or spacer in the preparation of peptide-drug conjugates (PDCs) and antibody-drug conjugates (ADCs). Its rigid aromatic structure provides stability and predictable reactivity. The growing field of targeted therapeutics, including ADC development by major biopharma companies, has increased demand for ultra-high-purity (≥99.5%) grades of this compound.
In fine chemicals, 4-aminophenylacetic acid is used to synthesize azo dyes, fluorescent whitening agents, and corrosion inhibitors. It also finds application as an intermediate for polymer stabilizers and UV absorbers. This segment grows at 3-5% annually, driven by industrial coating and textile demands.
Major Market Participants
The global supply system for 4-aminophenylacetic acid (CAS: 1197-55-3) features a pattern of “specialized fine chemical companies and Chinese manufacturers dominating large-scale production, with European and Japanese players focusing on ultra-high-purity and GMP grades.” Production relies on catalytic hydrogenation of 4-nitrophenylacetic acid or multi-step synthesis from phenylacetic acid.
In the global high-purity pharmaceutical segment, established players include: Bachem (Switzerland) offers GMP-grade 4-aminophenylacetic acid for peptide and ADC applications with purity ≥99.5% and strict residual solvent control. Merck KGaA (Germany) supplies research-grade and cGMP intermediates for early-stage drug development. In Japan, Watanabe Chemical Industries and Tokyo Chemical Industry (TCI) provide high-purity grades with full impurity profiling, serving the Japanese pharmaceutical and diagnostic industries.
In the specialty fine chemical segment, several European and American custom synthesis houses offer 4-aminophenylacetic acid and its derivatives (e.g., Boc-protected, methyl ester) for research and development purposes, with small-pack sizes and rapid delivery.
Regional Market Dynamics
Global demand for 4-aminophenylacetic acid shows regional differentiation: “Asia-Pacific dominates production and consumption, North America and Europe lead in high-purity and GMP-grade demand, and the rest of the world follows as net importers.” Asia-Pacific accounts for over 65% of global consumption, driven by antibiotic manufacturing in China and India.
China is the world’s largest producer and consumer of 4-aminophenylacetic acid, with annual production capacity estimated at 2,000-3,000 tons. The country’s integrated cephalosporin supply chain – from basic intermediates to finished dosage forms – creates steady domestic demand. Chinese pharmaceutical companies export both the intermediate and finished APIs to regulated markets. Environmental regulations have consolidated production to fewer, larger-scale, compliant facilities, raising quality standards.
India is the second-largest consumer, primarily for captive use in cephalosporin API production. Indian manufacturers benefit from lower labor costs and established export channels to Africa, Latin America, and Southeast Asia. However, reliance on Chinese starting materials (4-nitrophenylacetic acid) creates supply chain vulnerabilities.
North America and Europe account for approximately 20% of global demand, focused on high-purity (≥99.5%, GMP-grade) material for innovative drug development, ADCs, and research applications. The US and Swiss pharmaceutical hubs source from specialized suppliers with full regulatory documentation (DMF, CEP). Price sensitivity is lower, but compliance requirements are stringent (ICH Q7, cGMP).
Latin America and the Middle East/Africa are minor consumers, with limited local manufacturing of cephalosporins. They rely on imports from China and India.
Regulatory and Environmental Considerations
As a pharmaceutical intermediate, 4-aminophenylacetic acid (CAS: 1197-55-3) is not a final drug substance but its production and trade are subject to chemical control regulations and, when intended for pharmaceutical use, to GMP guidelines.
In the EU, 4-aminophenylacetic acid is registered under REACH as an intermediate (strictly controlled conditions exempt certain registration requirements). It is classified as a skin irritant (H315), eye irritant (H319), and may cause respiratory irritation (H335). Suppliers must provide Safety Data Sheets (SDS) and follow CLP regulations. For use as a pharmaceutical intermediate, importers need to comply with EU GMP guidelines and, if the final API is marketed, relevant marketing authorizations.
In the US, the EPA regulates it under TSCA; it is an existing substance. For pharmaceutical use, manufacturers must follow FDA guidance on intermediates under 21 CFR Parts 210 and 211 (cGMP). No specific FDA registration is required for the intermediate itself, but documentation of quality and purity is expected in API DMFs.
In China, 4-aminophenylacetic acid is listed in the “Inventory of Existing Chemical Substances” and is subject to environmental and safety regulations. Producers require a chemical production license and must comply with GB/T standards for product purity. For export to regulated markets, Chinese manufacturers obtain DMF filings and undergo customer audits.
In India, it is regulated under the Drugs and Cosmetics Act when used as a drug intermediate, and under the Manufacture, Storage and Import of Hazardous Chemical Rules for safety.
Environmentally, the hydrogenation process used in its production generates waste catalysts and requires careful management of hydrogen gas. Green chemistry initiatives focus on recyclable catalysts and continuous-flow hydrogenation to reduce waste and improve safety.
Future Outlook
The market outlook for 4-aminophenylacetic acid is tied to three drivers: the steady demand for cephalosporin antibiotics (especially in emerging markets), the growth of peptide-drug conjugates and ADCs in targeted cancer therapy, and the expansion of generic pharmaceutical manufacturing. The global market is expected to grow at a CAGR of 4-6% over the next five years.
On the demand side, first, the rising incidence of bacterial infections and antibiotic resistance sustains cephalosporin consumption. Second, the ADC market, projected to exceed $30 billion by 2030, will require high-purity linkers including 4-aminophenylacetic acid derivatives. Third, patent expiries of several cephalosporins will boost generic production, increasing demand for cost-effective intermediates.
Challenges include: environmental pressure on nitroaromatic hydrogenation processes, competition from alternative synthetic routes, and supply chain disruptions affecting raw material availability. Enterprises should invest in green hydrogenation technologies, secure regulatory filings (DMF, CEP), and develop derivative products (e.g., Boc-4-APA, 4-APA methyl ester) to capture higher value.
Shanghai XinChem Co., Ltd. (XinChem)
As a world-leading supplier of organic chemicals and pharmaceutical intermediates, Shanghai XinChem Co., Ltd. (XinChem) has always focused on the innovative needs of the pharmaceutical and fine chemical industries. Relying on core technological advantages in hydrogenation, purification, and quality control, we provide high-purity 4-Aminophenylacetic acid (CAS: 1197-55-3) to global customers. Our product is manufactured under strict quality management systems, fully complying with pharmaceutical intermediate standards. It is an ideal building block for antibiotic synthesis, peptide conjugation, and specialty chemical applications.
1. Technical Advantages
- High Purity: Our 4-aminophenylacetic acid achieves purity ≥99% (HPLC) with standard grade, and ≥99.5% for ultra-high-purity pharmaceutical grade.
- Low Impurity Profile: Strict control of residual solvents (≤0.5% total), heavy metals (≤20 ppm), and related substances (single impurity ≤0.1%).
- GMP Compliance: Available with full documentation, including Certificate of Analysis (COA), residual solvent report, and DMF support.
2. Product Advantages
- Bifunctional Reactivity: Amino and carboxylic acid groups enable diverse derivatizations (Boc-protection, esterification, amidation).
- Flexible Packaging: 25KG fiber drums (industrial), 5KG/1KG aluminum foil bags (R&D), custom packaging upon request.
- Reliable Supply Chain: Annual capacity 100-200 tons, with dedicated cool, dry storage (ambient temperature, avoid moisture).
3. Application Fields
- Pharmaceutical Intermediates: Cephalosporin antibiotics (cefaclor, cefprozil), fenamic acid derivatives, API synthesis.
- Peptide Conjugation: Linkers for peptide-drug conjugates (PDCs) and antibody-drug conjugates (ADCs).
- Fine Chemicals: Azo dyes, fluorescent whitening agents, corrosion inhibitors, polymer stabilizers.
4. Service Support
Our technical team provides impurity profiling, custom derivatization (e.g., Boc-APA, methyl ester), and regulatory support (DMF preparation, customer audits). We offer just-in-time delivery and competitive pricing.
5. Why Choose XinChem
- Professionalism: 20+ years in chemical and pharmaceutical intermediates.
- Flexibility: Tailored to customer purity and packaging requirements.
- Cost‑effectiveness: High quality at competitive prices.
Contact us now to start cooperation!
Website: www.xinchem.com
Email: sales1@xinchem.com
WhatsApp: +86 18049800532
Post time: Apr-14-2026